1. Home
  2. HXHX vs NRXP Comparison

HXHX vs NRXP Comparison

Compare HXHX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HXHX
  • NRXP
  • Stock Information
  • Founded
  • HXHX 2003
  • NRXP 2015
  • Country
  • HXHX China
  • NRXP United States
  • Employees
  • HXHX N/A
  • NRXP N/A
  • Industry
  • HXHX Trucking Freight/Courier Services
  • NRXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • HXHX Industrials
  • NRXP Health Care
  • Exchange
  • HXHX Nasdaq
  • NRXP Nasdaq
  • Market Cap
  • HXHX 36.9M
  • NRXP 32.6M
  • IPO Year
  • HXHX 2025
  • NRXP N/A
  • Fundamental
  • Price
  • HXHX $1.45
  • NRXP $2.45
  • Analyst Decision
  • HXHX
  • NRXP Strong Buy
  • Analyst Count
  • HXHX 0
  • NRXP 4
  • Target Price
  • HXHX N/A
  • NRXP $28.50
  • AVG Volume (30 Days)
  • HXHX 244.5K
  • NRXP 246.4K
  • Earning Date
  • HXHX 01-01-0001
  • NRXP 05-15-2025
  • Dividend Yield
  • HXHX N/A
  • NRXP N/A
  • EPS Growth
  • HXHX N/A
  • NRXP N/A
  • EPS
  • HXHX 0.26
  • NRXP N/A
  • Revenue
  • HXHX $25,571,810.00
  • NRXP N/A
  • Revenue This Year
  • HXHX N/A
  • NRXP N/A
  • Revenue Next Year
  • HXHX N/A
  • NRXP N/A
  • P/E Ratio
  • HXHX $5.37
  • NRXP N/A
  • Revenue Growth
  • HXHX N/A
  • NRXP N/A
  • 52 Week Low
  • HXHX $1.35
  • NRXP $1.10
  • 52 Week High
  • HXHX $6.29
  • NRXP $6.01
  • Technical
  • Relative Strength Index (RSI)
  • HXHX N/A
  • NRXP 69.12
  • Support Level
  • HXHX N/A
  • NRXP $2.16
  • Resistance Level
  • HXHX N/A
  • NRXP $2.35
  • Average True Range (ATR)
  • HXHX 0.00
  • NRXP 0.15
  • MACD
  • HXHX 0.00
  • NRXP 0.05
  • Stochastic Oscillator
  • HXHX 0.00
  • NRXP 85.83

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: